|
|
The Synosia team bring their individual strengths, expertise and experience to form an organisation that can successfully drive the development of new treatments for disorders of the central nervous system (CNS). Their combined backgrounds cover the life cycle of drug development, from business development to preclinical and clinical development as well as regulatory and financial.
Collectively, they have some 200 years working in pharmaceutical and biotech drug development. During that time, they have helped bring many new drugs to the market.
IAN MASSEY DPhil
Chief Executive Officer & President
 Ian Massey is a seasoned pharmaceutical industry senior executive with 30 plus years experience covering all phases of the research and development process across multiple therapeutic areas. A chemist by training, he directed or made a major contribution to the discovery, preclinical development and early clinical development of approximately 40 new chemical entities that entered clinical studies. More than 20 of those progressed at least to Phase II/clinical proof-of-concept studies.
Before becoming Synosia’s first chief executive officer, Ian was senior vice president of research and preclinical development for Roche Palo Alto where he had built a scientifically strong research and preclinical development group. Ian had been with Roche for 11 years and had played a key leadership role in the creation and strategic design of Roche Bioscience, an entrepreneurial organization created when Roche acquired Syntex in 1994. Prior to joining Roche, Ian was with Syntex Research for 17 years, serving in a variety of R&D management roles.
An author of numerous publications, Ian earned his doctorate in organic chemistry from the University of Oxford, England, and was a postdoctoral research fellow at Stanford University. He has a bachelor’s degree in chemistry with first class honors and a master’s degree in organic/natural product chemistry.
STEVE BANDAK MB BS MRCP
Chief Medical Officer
 Steve Bandak is a physician with a depth of experience in the CNS area. During his career he has had a range of responsibilities, including the design and conduct of clinical studies, building clinical research capabilities and successfully negotiating with regulatory authorities
He most recently served as vice president of medical and regulatory affairs with Novavax, Inc. in Rockville, MD., but the majority of his career was with pharmaceutical giant Eli Lilly where he rose to the position of Medical Director. At Lilly, Steve was involved in the development of Prozac®; Zyprexa®, Cymbalta® and Strattera® as well as building clinical research capabilities and successfully negotiating with regulatory authorities.
Steve was educated and trained in Guy's Hospital Medical School, University of London and did his internship and internal medicine residency at Guy's Group Hospitals in London and neurology residency at the Royal Free Hospital in London.
LESLEY PICKFORD PhD MBA
Vice President, Preclinical Safety & Pharmacology
 Lesley Pickford has extensive experience in both the biotech and pharmaceutical industries and in academic research. During the 21 years she has worked in research and development (R&D), she held various leadership positions with responsibilities from discovery through to commercial release. She had key management roles in the discovery, preclinical phases and clinical development of several candidates, leading to marketing approvals.
Before joining Synosia, Lesley was with ALZA Corporation, working on the global approval and product release for a new product for chronic pain. Previously, she held senior management positions at Calyx Therapeutics, Corixa Corporation and Connectics Corporation, including establishing pharmacology and toxicology departments.
Lesley holds numerous patents and has extensive publications to her credit. She earned her doctorate in medical biochemistry from Flinders University of South Australia and was a postdoctoral fellow in pathology and psychiatry at Stanford University. Her bachelor's degree is in biochemistry and physiology with first class honors from Adelaide University, and she received her master's of business administration from the Executive Program at Leavey School of Business at Santa Clara University.
ANN NEALE RN BSN
Vice President, Clinical Operations
 Ann Neale has more than 18 years of clinical development experience in the pharmaceutical/biopharmaceutical industry in the United States, Canada and Europe. Ann brings both therapeutic and business experience to Synosia and expertise in strategic planning to take lead molecules into clinical development.
Before joining Synosia, Ann was vice president of clinical operations at Saegis Pharmaceuticals, responsible for the strategic planning and clinical development of the company's central nervous system (CNS) compounds. She also has extensive experience in development operations for other companies including ARYx Therapeutics and Mimetix Incorporated, as well as being a principal in WinPharm Associates, a clinical drug development consulting company.
Ann received her bachelor's of science in nursing degree from the University of Minnesota and is the author of a several publications and abstracts.
UWE MEYA MD
Vice President, Clinical Research & Development
 Uwe Meya is a board-qualified neurologist and psychiatrist by background with an impressive track record in pharmaceutical research and development, focused on disorders of the central nervous system (CNS). His experience spans multiple CNS indications and covers the full spectrum of drug development from first-in-man through to regulatory filing.
He was most recently head of research portfolio management for Roche in Basel, where he contributed to the global strategic direction of all therapeutic areas. While at Roche and Novartis, he worked on several of the compounds subsequently out-licensed to Synosia and received the Roche Global Development Leadership Reward in recognition of his effectiveness in building relationships and partnerships.
Prior to joining Roche in Basel, Uwe was with Novartis where he managed a team of researchers in CNS clinical development and later served as a member of a special clinical development management team, overseeing projects from late pre-clinical studies through to the end of Phase I. He previously worked at Ciba-Geigy, Knoll and Schering in CNS research.
Uwe was educated in Germany and studied medicine in Aachen, Germany and Glasgow, Scotland. He received his medical degree from the University of Aachen, where he also completed a doctorate in psychiatry.
He is a member of the European College of Neuropsychopharmacology and is a founding member of the International College of Geriatric Psychoneuropharmacology, where he served as a council member for more than three years.
THOMAS MALEFYT PhD
Vice President, Technical Operations
 Tom Malefyt has significant pharmaceutical industry experience in manufacturing, pre-formulation evaluation, formulation, analysis, documentation, and registration of new drugs.
Prior to joining Synosia, Tom led a pharmaceutical start-up effort to evaluate and refine a cell-specific drug delivery technology and an antigen-specific T-cell modulation technology from the University of Kansas.
Since first joining the pharmaceutical industry at SmithKline and French Laboratories in 1984, Tom has acquired experience in managing the chemistry, manufacturing and controls (CMC) development of both early-phase and late-phase drug candidates, in both large and small pharmaceutical companies. Tom joined Syntex Research (later Roche) in 1988, where he held positions of increasing leadership and responsibility. He has developed traditional small molecule, peptide, recombinant vaccine and protein drug candidates.
Tom earned his doctorate in chemistry at the University of California, Santa Barbara, and gained further experience with postdoctoral fellowships at the University of Queensland (enzymology), and the University of Kansas (pharmaceutical chemistry).
MICHAEL EISON Phd
Vice President, Regulatory Affairs
 Michael Eison is an experienced drug developer and a seasoned veteran of regulatory affairs. He spent the first 15 years of his career in central nervous system (CNS) drug discovery/science management and the subsequent 11 years in regulatory affairs formulating regulatory strategies that anticipate the needs of the marketplace as well as those of worldwide health authorities.
Most recently, he was vice president of research and development for the Palo Alto site of Stiefel Laboratories, but the majority of his career was with the Bristol-Myers Squibb Company. He joined them as a scientist in 1981 and ultimately became the director of CNS drug discovery before changing career direction and becoming a director in regulatory affairs. He joined InterMune in 2002 as senior director regulatory affairs and Connetics in 2005 as vice president of regulatory affairs.
Michael earned his bachelor's degree in psychology in 1975 at the State University of New York at Buffalo and was awarded his doctorate in physiological psychology/psychopharmacology from UCLA in 1980.
KATHLEEN MARTIN PhD
Senior Director, Project & Portfolio Management
 Kathleen Martin is an accomplished project and alliance manager with a track record of planning and executing development projects to achieve business and project objectives. She brings broad drug discovery experience to Synosia, including responsibility as head of the program management function, project manager, alliance manager and research project leader.
From 2001 to 2006 when she joined Synosia, Kathleen was with Renovis, Inc, where she held a number of key management positions. Before joining Renovis, she worked in neurobiology at Incyte Genomics and at Chiron Corporation in small molecule drug discovery and growth factor discovery.
A holder of two patents and author of numerous publications, Kathleen earned a doctorate in neurobiology from Yale University School of Medicine, a master's of science degree in psychology, also from Yale, and conducted postdoctoral research at the Howard Hughes Medical Institute at UCLA.
MICHAEL MULQUEEN BSc
Vice President, European Operations
 Michael Mulqueen brings to Synosia knowledge of business development and alliance management, along with a scientific background. Most recently, he was global head of alliances at Roche and a member of several senior decision-making bodies within Roche.
From 1988 to 2001, Michael worked in the Roche United Kingdom research group on both anti-inflammatory and anti-viral projects and was actively involved in managing several key relationships with external partners. Prior to joining Roche, he worked for seven years in the inflammation research unit at Rhone Poulenc Rorer.
He holds a bachelor's degree in pharmacology from the University of Liverpool, England.
ZACHARY MCNEALY
Vice President, Finance
 Zack McNealy has 10 years of experience as a financial analyst, finance manager and controller for healthcare companies. During his career, he has provided analysis and recommendations on multi-million dollar development budgets, as well as managed all finance activities related to sales and marketing for major products.
Before joining Synosia, Zack was with two Johnson & Johnson companies - Cordis Corporation, where he last served as controller for their LuMend, Inc plant, and Ethicon Endo-Surgery, where he worked as a financial analyst both in sales and marketing and in research and development.
Zack, a certified management accountant who is also certified in financial management, received his bachelor's of science degree in accounting and finance from Ohio's Miami University.
|
|
|
|